A20: a master regulator of arthritis

Yongyao Wu¹, Xiaomin He¹, Ning Huang¹, Jiayun Yu² and Bin Shao¹,²*

Abstract

A20, also known as TNF-α-induced protein 3 (TNFAIP3), is an anti-inflammatory protein that plays an important part in both immune responses and cell death. Impaired A20 function is associated with several human inflammatory and autoimmune diseases. Although the role of A20 in mediating inflammation has been frequently discussed, its intrinsic link to arthritis awaits further explanation. Here, we review new findings that further demonstrate the molecular mechanisms through which A20 regulates inflammatory arthritis, and we discuss the regulation of A20 by many factors. We conclude by reviewing the latest A20-associated mouse models that have been applied in related research because they reflect the characteristics of arthritis, the study of which will hopefully cast new light on anti-arthritis treatments.

Keywords: A20, Arthritis, Zinc finger domains, Inflammation, Mouse models

Introduction

Arthritis has long attracted much attention due to its multifaceted influence on human health; the three most common types are rheumatoid arthritis (RA), osteoarthritis (OA), and spondyloarthritis (SpA) [1]. RA, characterized by painful swollen joints and progressive bone erosion, is an autoimmune disease that severely impairs physical function and quality of life [2]. OA is the primary cause of disability and source of societal expenditure in elderly adults, which has become even more prevalent recently than it has been in preceding decades [3]. What is worse, there have been non-significant differences to patients’ mortality risk and functional disability between a decade ago and now, but patients’ expectations of efficient treatment have increased [4]. Therefore, it is meaningful to explore innovative therapeutic strategies for arthritis.

RA, OA, and SpA can be distinguished based on their diversity in pathogenesis and manifestations, but they demonstrate analogous inflammatory features; however, not all signs of inflammation appear in joints [1]. In addition, many inflammation-related pathways, such as the tumor necrosis factor receptor (TNFR)-induced nuclear factor kappa B (NF-κB) pathway, mitogen-activated protein kinase (MAPK) signaling, and Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling, are highly associated with these diseases [5–7]. Pro-inflammatory family members, which can be detected in the articular environment when arthritis occurs, are associated with the degree of inflammation present [8]. On the one hand, some pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin (IL)-6, and IL-1, facilitate the development of arthritis [9]. On the other hand, IL-4, IL-10, IL-37, and IL-38 play the role of relieving inflammation to restrict arthritis [10], particularly A20.

A20, also known as TNF-α-induced protein 3 (TNFAIP3), was originally discovered in 1990 by Dixit [11]. It is a highly conserved protein that contains an amino-terminal ovarian tumor (OTU) domain in its N-terminus and seven zinc finger (ZnF) domains in its C-terminus. The OTU domain mediates deubiquitinating (DUB) activity, and the ZnF4 and ZnF7 domains bind to K63-linked Ub (ubiquitin) chains and M1-linked Ub

* Correspondence: sklbshaobin@scu.edu.cn
† Yongyao Wu, Xiaomin He and Ning Huang contributed equally to this work.
¹State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
²State Key Laboratory of Biotherapy anf Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
chains, respectively, and support E3 Ub ligase activity (Fig. 1). Therefore, A20 acts as an “ubiquitin-editing” enzyme because it possesses both deubiquitinating and ubiquitinating abilities [12, 13]. After decades of study, the capabilities of A20 have been revealed to a certain extent. A20 has been well established as a negative regulator of NF-κB in response to TNF, IL-1, IL-17, and so on [12, 14], though there are paradoxical in vitro and in vivo findings about the role of A20 in attenuating inflammatory signaling [15]. Improper activation of NF-κB implicates the development of chronic inflammation and cell death and is thought to be a therapeutic target for arthritis, though it plays a key role in activating the innate and adaptive immune system to protect against infection and promote survival [16, 17]. In these processes, A20 is thought to disrupt the ubiquitination status of specific signaling proteins in the TNFR and Toll-like receptor (TLR) pathways to inhibit NF-κB signaling [18, 19], which occurs via the deubiquitinating activity of the OUT domain and the inverse Ub-binding function of ZnF domains [12]. Gradually, new anti-inflammatory functions, such as regulating the activation of inflammasomes and restricting the secretion of pro-inflammatory cytokines such as interleukin [20], are being identified for A20, further demonstrating its potential roles in anti-inflammation.

The inflammatory features of arthritis and the anti-inflammatory function of A20 suggest that A20 can suppress arthritis by restricting inflammation, which has been verified by a growing number of studies. Evidence for the antiarthritis function of A20 was provided by myeloid-A20-deficient mice, which developed swelling and redness of the front and hind paws that reached 100% at 20 weeks of age, as shown by Matmati et al. [21]. Thus, A20 has established its position as a potential molecule that could affect the course of arthritis. Recent studies have made further progress on understanding A20 and have shown that it protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and linear ubiquitin-independent mechanisms [22, 23]. It has also been confirmed recently that there is a tight association between TNFAIP3 gene polymorphisms and RA susceptibility [21, 24, 25]. In addition, A20 haploinsufficiency (HA20) can cause early-onset inflammatory arthritis in humans [26], which further illustrates the significant role of A20 in arthritis. A recent study even revealed that increased expression of type I interferon (IFN) was correlated with autoinflammatory disease activity in HA20 patients, while A20 was capable of restraining the type I IFN response, though the underlying mechanism needs further exploration [27]. The highlight of these studies is that the ZnF4 and ZnF7 ubiquitin-binding domains in A20 have been proven to be critical to the function of preventing inflammation-dependent arthritis [28–30], and exploration of the...
specific role of these domains has gradually progressed. For example, several mouse models have proven that the ZnF7 domain of A20 has a particular status in regulating spontaneous immune activation and preventing cell necroptosis; further ZnF4 plays a role in the process, as it has the property of acting synergistically with ZnF7 [28, 29].

In this review, we summarize some antiarthritic mechanisms of A20 based on its anti-inflammatory features and summarize factors affecting A20 expression. We also highlight the review by listing mouse models that can simulate arthritis for the A20 study, which could facilitate research on this promising protein.

**Key molecules implicated in the pathogenesis of arthritis**

A severe and persistent inflammatory response is one of the hallmarks of arthritis. Previous studies revealed that environmental and hereditary factors trigger arthritis by protein modification, mutation, and immune cell activation [9, 31] (Fig. 2). During this process, cytokines, such as TNF and IL-6, also play a critical role in the pathogenesis of inflammation in arthritis. TNF aggregates peripheral MDSCs, which are ubiquitous in inflammation [32]. Meanwhile, TNF-α could also induce an inflammatory response, which involves the activation of leukocytes, cytokines, and chemokines, stimulating the formation of osteoclasts and promoting the resorption of cartilage and bone [9]. IL-6 also activates leukocytes and osteoclasts and increases autoantibody production, which is closely related to OA [33]. In addition, IL-1β, IL-6, IL-21, and IL-23 support the differentiation of T helper 17 (Th17) cells, suppress the differentiation of regulatory T cells, and cause inflammation of arthritis [9]. IL-17 has powerful properties in inducing neutrophil-attracting chemokines to initiate and promote inflammation and helps to destroy cartilage and increase osteoclast differentiation, leading to bone erosion in joints [9, 34, 35]. Moreover, the sustained activation of the IL-17 axis leads to an accumulation of immune cells in the synovium and increased intercellular interactions, thereby forming a pro-inflammatory environment that could in turn promote the synergistic collaboration of IL-17 with TNF-α, IL-1β, IL-18, and many other cytokines [35]. This further aggravates inflammation.

Moreover, the intracellular signaling pathways related to inflammation in arthritis involve NF-κB, Janus kinase (JAK), MAPK, and so forth (Fig. 2). NF-κB can be independently activated by TNFR-1, Toll-like receptor, IL-1R, and others [36]. In addition, MAPK is considered to be the intersection of multiple signaling pathways and the upstream signal of the NF-κB signaling pathway, as the activated MAPK signaling pathway participates in mediating the activation of NF-κB [9]. However, strategies targeting these pathways might enable therapeutic avenues for relieving the symptoms of arthritis.

Accordingly, the strategy of targeting these cytokines with inhibitors and neutralizing antibodies is widely used in arthritis therapy [10, 31]. TNF-α inhibitors can significantly improve the clinical symptoms of human TNF transgenic (hTNFtg) mice with spontaneous arthritis, and they are frequently used in patients with severe RA [37, 38]. IL-6-receptor antibodies in RA treatment, such as tocilizumab, showed outstanding efficacy [39]. In addition, it has been reported that granulocyte-macrophage colony-stimulating factor (GM-CSF) inhibition is effective in treating RA [40].

**Mechanism of A20 regulating arthritis**

**A20 restricts arthritis development by controlling TNF and the interleukin signaling pathway**

As mentioned above, TNF-α inhibitors have been frequently used to treat severe RA [38] because of the pioneering status of TNF-α at the apex of the pro-inflammatory cytokine cascade [6, 41]. Moreover, the activation of TNF-induced TNFR signaling and downstream signaling evoked by TNFR, such as NF-κB and MAPK, implicates a variety of responses. For example, activated NF-κB further reinforces inflammation by triggering the formation of numerous pro-inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, and repressing IL-4 [17]. Additionally, when TNFR1 and receptor interacting protein kinase 1 (RIPK1) are modified by lysine-63 (K63)-linked ubiquitin ligases, they can generate a signaling complex that facilitates NF-κB activation [42].

Otherwise, in ablation of TNFAIP3/A20, upon TCR and CD28 co-stimulation and with the help of a TNF inhibitor, protein kinase C (PKC) and p38 MARK signaling are in an active state, leading to a dramatic increase in the number of Th17 cells circulating in the blood, and the level of IL-17a correspondingly increases [43]. Another study reported that a tendency towards high levels of type I IFN can be detected during anti-TNF-α therapy, which has been deemed a marker of anti-TNF-α failure. Therefore, it is reasonable to hypothesize that elevated IL-17a, type I IFN, and other cytokines during the use of TNF inhibitors might be the reasons for the failure of these treatments [38].

A20 is a ubiquitin-editing enzyme that can edit a variety of ubiquitin chains through corresponding Ub-dependent biochemical motifs. The OTU domain of A20 functions as a DUB that cleaves K63-linked polyubiquitin chains, and phosphorylation of A20 at Ser381, which is mediated by IKKβ, can improve its DUB activity. ZnF4 can bind to E2 enzymes and then inhibit E3 ligase activity dependent on these enzymes, which ultimately enables the building K48-linked polyubiquitin chains. ZnF7 binds to M1-linked polyubiquitin and competes with
other Ub-binding proteins to prevent the degradation of M1-linked chains [12, 13] (Fig. 1). These findings reveal that A20 is involved in the pathological processes described above in the following ways. First, A20 has the capacity to restrict NF-κB activation in response to TNF, IL-1, lipopolysaccharide (LPS), IL-17, and so on by inhibiting the inhibitor of κB (IκB) kinase (IKK) complex through a mechanism that is dependent on recruitment to the nuclear factor-κB essential modulator (NEMO) C-terminus [44] (Fig. 3a-c) (Upon TNF stimulation, the linear ubiquitin chain assembly complex (LUBAC) is recruited to the TNFR complex and then modifies NEMO to facilitate IKK activation, while ZnF7 can bind to both NEMO and LUBAC and prevent the TNF-induced binding of NEMO to LUBAC, which demonstrates the non-catalytic binding function of ZnF7 in attenuating NF-κB activity [45]. Furthermore, A20 removes K63-linked ubiquitin chains from RIPK1 and TNFR1 in a process that is dependent on the catalytic residue Cys103 (C103)-based deubiquitinating activity of the OTU domain, and then A20 adds lysine 48 (K48)-linked ubiquitin on RIPK1 though the E3 Ub ligase activity of ZnF4, thus targeting RIPK1 for proteasomal degradation and leading to dissociation of a RIPK1-containing complex from the membrane in a process that results in reducing TNF-induced and NF-κB-supported survival [6, 19]. Thus, A20 protects cells from TNF-induced and NF-κB-mediated inflammation and arthritis (Fig. 3a). Moreover, during anti-TNF therapy, IL-17 expression is increased, which is due to a tendency for MAPK to be at a highly active state [43]. A20 can block IL-17 production by interrupting the MAPK signaling pathway through abrogating K63 ubiquitination of TNF receptor associated factor 6 (TRAF6) and preventing
the prolonged phosphorylation of c-Jun-N-terminal-kinase (JNK), which are both important for MAPK activation [46]. Moreover, it has been substantiated in some experiments that p38 MARK and PKC activity are inhibited when A20 is present [5], thus blocking IL-17 production and inflammatory aggravation mediated by IL-17 during anti-TNF treatment (Fig. 3b-c). More recently, it has been shown that A20 restricts Th17 cell expansion and arthritis through its ZnF7 motif [28].

Therefore, in the TNF-α inflammatory pathway, which is upstream of the inflammatory response, A20 can target RIPK1 for proteasomal degradation, thus protecting cells from NF-κB activation and the subsequent production of pro-inflammatory factors. A20 can block IL-17 production and IL-17-mediated inflammatory aggravation during anti-TNF treatment by preventing the prolonged phosphorylation of JNK and inhibiting p38 MARK and PKC activity, which is dependent on the ZnF7 motif of A20. As a result, the development of IL-17 production is blocked, leading to a reduced inflammatory response.
arthritis is repressed. However, the DUB activity of A20 in vivo and in vitro experiments is controversial. In vitro studies suggest that A20 restricts NF-κB signals via C103-based DUB activity, while in vivo, DUB activity does not play a role in directly inhibiting NF-κB and is dispensable for the regulation of NF-κB signaling [15]. Interestingly, a recent study showed that A20's ZnF7 domain probably also directly regulates NF-κB signaling and that it is independent of A20's C103-based deubiquitinating activity [28]. A mixture of K63-linked and M1-linked Ub chains exists in IKK complexes, which could be recognized by ZnF4 and ZnF7, resulting in the restriction of IKK activity. ZnF7 is involved in this process though supporting the E3 ligase activity of ZnF4 on RIPK1 and directly restricting the activity of IKK by resulting from its noncatalytic binding function [23, 28]. Therefore, it can be assumed that the E3 ligase activity of ZnF4 and the noncatalytic binding function of ZnF7 could compensate for the attenuated deubiquitinating function in vivo to restrict TNF-mediated induction of NF-κB.

**A20 restricts arthritis development by controlling NLRP3 inflammasome activity**

Genetic variations in proteins, namely, NLRP3 of the NLRP3 inflammasome complex, have been reported to influence the susceptibility and severity of RA [47]. NLRP3 inflammasomes are a group of cytoplasmic protein complexes that are assembled by intracytoplasmic pattern recognition receptors (PRRs), which are a type of molecular platform that can respond to danger and promote maturation and secretion of IL-1β and IL-18 [48] (Fig. 3d). Priming of the NLRP3 inflammasome is promoted through activation of NF-κB, which is induced by microbial or endogenous molecules, and the NLRP3 inflammasome is activated by secondary signals such as ATP, pore-forming toxins, and viral RNA [49]. Moreover, priming of the inflammasome can further positively regulate NLRP3 activation at the posttranscriptional level [49]. Therefore, when cells are stimulated with dangerous factors, gene transcription is upregulated for inflammasome components, such as NLRP3, caspase-1 (Casp1), and apoptosis-associated speck-like protein containing a CARD (ASC); the upregulation is accompanied by increased expression of inflammasome substrates pro-IL-1β, pro-IL-18, and gasdermin-D (GSDMD), which is followed by the assembly of the inflammasome [50]. The assembly of inflammatory bodies triggers active Casp1-dependent proteolytic cleavage, which causes the cytokine precursors pro-IL-1β and pro-IL-18 to mature and become biologically active, producing IL-1β and IL-18, respectively [51]. IL-1β recruits innate immune cells to the site of infection and mediates cartilage destruction [52], along with IL-18, which promotes cell lysis and interferon-γ (IFN-γ) production to accelerate the development of inflammation [49].

The levels of NLRP3 and pro-IL-1β in A20-deficient cells are higher than those of wild-type macrophages at rest and those that have been primed with LPS [53]. This evidence suggests a strong connection between A20, the inflammasome, and pathogenesis of RA. A20 can limit the inappropriate activity of this inflammasome by restricting its assembly and suppressing activation of Casp1. First, NLRP3 priming is accomplished by NF-κB activation and translocation of NF-κB, which leads to increased synthesis of NLRP3 so that A20 could exert its NF-κB suppressing function to downregulate NLRP3 inflammasome assembly [54]; further, A20 can also lower the basal expression of NLRP3 directly to impair inflammasome activation [20]. Interestingly, A20's ZnF7 motif cannot prevent spontaneous NLRP3 inflammasome activation, whereas its ZnF4 and ZnF7 motifs synergistically restrict NLRP3 inflammasome activity [28]. Moreover, as described above, activation of the NLRP3 inflammasome accompanies Casp1 maturity, whereas Casp1 helps mature macrophages and excretes cytokines that promote inflammation [51]. Significant Casp1 activity can also cause pyroptosis, subsequently activating the inflammasome to produce a damage-related molecular pattern (DAMP), which directly drives secretion of pro-inflammatory cytokines [49]. A20 has the ability to inhibit pyroptosis through a mechanism that is dependent on Casp1, thereby preventing the maturation of pro-IL-1β, but the exact mechanism remains unknown [20] (Fig. 3d). Additionally, the substrate of Casp8, which derives from the fraction of RIPK1, is cleaved in pro-IL-1β complexes in A20-deficient cells, and matured Casp8 can accelerate the maturity of pro-IL-1β and mediate apoptosis [55]. However, RIPK1 tends to degrade, and the production of Casp8 is blocked when A20 is present [56] (Fig. 3a).

This evidence suggests that A20 suppresses arthritis development by dampening the function of NLRP3 in several ways. First, A20 downregulates the priming (transcription of inflammasome components) of the NLRP3 inflammasome by limiting the activation of NF-κB, and the activation of NLRP3 is correspondingly restricted, causing a low level of priming. Second, A20 represses Casp1-dependent pyroptosis and the maturation of pro-IL-1β to reduce the production of IL-1β and IL-18. Third, A20 decreases the quantity of Casp8 stemming from RIPK1 to reduce Casp8-dependent apoptosis and the production of IL-18.

**A20 prevents arthritis by inhibiting macrophage necroptosis and restricting spontaneous immune activation through its ZnF7**

Necroptosis is a modified form of necrosis in which dead cells break up and release intracellular components,
triggering an innate immune response that includes IL-1β release and NLRP3 inflammasome activation [29, 57]. TNFR and RIPK1 mediate intramolecular signaling and necroptosis. TNFR1 recruits an early complex composed of TNFR1-associated death domain protein (TRADD) and RIPK1. In the absence of caspase 8 activity, cellular inhibitors of apoptosis (cIAPs), and LUBAC, RIPK1 can recruit RIPK3 and then forms the RIPK1-RIPK3 complex called the necrosome [57]. Later, mixed-lineage kinase domain-like protein (MLKL) is recruited to this complex and phosphorylated by RIPK3, and the formation of active oligomers leads to plasma membrane destabilization and subsequent necroptosis [57, 58].

A20 can protect cells from necroptosis through its E3 ubiquitin ligase and DUB activities. The kinase activity of RIPK1 and RIPK3 is crucial to the formation of necrosomes, and the phosphorylation and ubiquitination status of RIPK3 as well as the presence of K63-linked polyubiquitin chains are indispensable to the RIPK-dependent necroptosis [57, 58]. As mentioned above, A20 can target RIPK1 for proteasomal degradation by replacing its K63-linked ubiquitin chain with the K48-linked ubiquitin chain and then restricting subsequent signaling, which leads to necroptosis [6, 19, 58]. Additionally, A20 also inhibits RIPK3 ubiquitination with K63-linked polyubiquitin chains through its DUB activity. Interestingly, in A20-deficient mouse embryo fibroblasts (MEFs), more RIPK1-associated RIPK3 phosphorylation is observed than that in WT MEFs after TNF-CHX-ZVAD induction [58], suggesting that A20 reduces the phosphorylated RIPK3, which is dependent on the formation of pro-necrotic RIPK1-RIPK3 complexes, and further inhibits RIPK3-dependent and phosphorylated MLKL-mediated necroptosis. However, there is a research which showed an inverse effect of A20 in regulating RIPK1. It suggested that elevated A20 expression in inflammatory bowel disease enfeebles the deubiquitination of TNFR1-associated RIPK1 and potentiates intestinal epithelial cell death. It may owe to that A20 dimer binds to linear ubiquitin chains via ZnF7 thus preventing RIPK1 degradation and then enhances caspase-8 activation [59]. And this study is consistent with the research we described above, which shows attenuated function of C103-based DUB activity in vivo.

A20 is also capable of protecting cells from necroptosis independent of its E3 ubiquitin ligase and DUB activities. Recent studies have demonstrated that A20 inhibits macrophage necroptosis via its ZnF7 domain [29, 30]. ZnF7 is vital to the emergence of inflammatory arthritis observed in A20mZnF7/mZnF7 (knock-in mice expressing A20 with dual cysteine-to-alanine mutations in ZnF7), as mutations in the ZnF7 domain abrogate the recruitment of TNFR1 signal complexes and diminish linear ubiquitin chains linked to these complexes [60]. A20 stabilizes the M1 (methionine 1)-linked ubiquitin chain connection of TNFR1 signal complexes through its ZnF7 domain to protect them from being degraded by DUBs, which cut linear ubiquitin chains. When harboring abnormal mutations in its ZnF7 domain, the A20mZnF7/mZnF7 phenotype ultimately develops inflammation [29] (Fig. 3a). These results indicated that the recruitment of A20 to complex 1 is dependent on ZnF7 and might be related to the inhibition of macrophage necroptosis.

Moreover, the newly generated mouse model A20ZFT7-CC/ZF7-CC (knock-in mice expressing A20 with dual cysteine-to-alanine mutations in ZnF7) has been found to have markedly increased memory phenotype T cells, which are capable of sustaining synovitis and promoting osteoclast differentiation in RA patients [28, 61]. In addition, enhanced NF-κB and JNK signaling have been discovered in naïve A20ZFT7-CC/ZF7-CC T cells. Interestingly, these activities were mild in A20DTU/DTU (mice with cysteine-to-alanine mutation of A20’s catalytic cysteine C103) and A20ZF4/ZF4 mice (mice with dual cysteine-to-alanine mutations in A20’s ZnF4 domain) [28]. Therefore, the ZnF7 domain of A20 has been found to have a special and significant status in suppressing T cell activation and expansion. Furthermore, A20ZFT7-CC/ZF7-CC and A20ZF4/ZF4 macrophages exhibited IL-1β secretion that was restricted by the NLRP3 inflammasome after LPS induction. Inversely, A20ZF4/ZF7 macrophages showed enhanced NLRP3 inflammasome-mediated caspase-1 activation and pyroptosis, and it illustrated the synergistic function of A20’s ZnF4 and ZnF7 motifs in restricting NLRP3 inflammasome activity and resulting in spontaneous pathology [30]. Together, this evidence illustrates the significance of the ZnF7 domain of A20 in restricting spontaneous immune activation.

Thus, the significance of the ZnF7 domain in necroptosis and spontaneous immune activation has been emphasized, bringing the study of A20 to a new place. This inspired and motivated us to explore more functions of this domain (Table 1).

**Mechanism of regulation of A20 TNF-α and interleukin**

As its name implies, A20 is notably regulated by TNF-α. TNF-α, IL-1β, IL-17, and other regulators of NF-κB can contribute to the expression of A20 at the transcriptional level by inducing binding to NF-κB binding sites in the A20 promoter [36, 46, 62]. Additionally, TNF-α also increases nuclear expression of GSK3β, thus promoting sustained expression of A20 and terminating NF-κB activity [63]. Meanwhile, A20 not only suppresses NF-κB activity, contributing to reduced production of TNF-α, IL-1β, IL-6, and other cytokines [19, 44], but also regulates IL-1β and IL-17 through TRAF6 and
MAPK [5, 46]. As a result, a negative feedback regulation mechanism is formed.

**Adiponectin**

Adiponectin, which is secreted mainly by adipocytes, is a vascular protective molecule with insulin-sensitizing, anti-inflammatory, and anti-atherogenic properties [64]. Adiponectin can augment the expression of A20 rapidly and observably by stimulating glucose synthase kinase $3\beta$ (GSK3$\beta$) activity, resulting in macrophage quiescence and initiating an A20-mediated anti-inflammatory program [65]. Consequently, adiponectin attenuated arthritis severity by suppressing pro-inflammatory markers in a preclinical model of collagen-induced mouse arthritis [66].

**Transcription factors**

The downstream regulatory element antagonist modulator (DREAM) is a member of the recoverin subfamily of neuronal calcium sensors, the deficiency of which relieves arthritis inflammatory pain; DREAM is highly expressed in immune cells such as purified CD4$^+$ and CD8$^+$ T cells [67, 68]. DREAM is a major transcriptional regulator of A20 gene expression, which it achieves through binding to the promoter of the gene encoding A20 [69]. In quiescent states, DREAM is bound to the downstream responsive elements (DREs) to repress A20 transcription in the A20 promoter, which is regulated by Ca$^{2+}$ and interacts with phosphoCREM (cAMP-responsive element modulator). In contrast, upon LPS stimulation, DREAM detaches from DNA to enable the binding of transcription factor upstream stimulatory factor 1 (USF1) to the DRE-associated E-box domain in the gene encoding A20, thereby activating A20 transcription [69]. In general, reduced levels of DREAM protein and activity lead to clearly increased A20 transcription and improved A20-mediated anti-inflammatory response.

Meanwhile, there are other transcription factors regulating the expression of A20, such as orphan nuclear estrogen-related receptor $\alpha$ (ERR$\alpha$) and Ash1l [70, 71]. ERR$\alpha$ directly binds to the A20 promoter region to promote expression [70], and Ash1l upregulates A20 through H3K4 methylation of the A20 promoter in macrophages [71]. In contrast, methylation of the A20 promoter has also been observed in lymphomas, and it prevents expression of A20 and stimulates NF-$\kappa$B activation [72].

**microRNA**

It has been reported that A20 can be regulated by many microRNAs (miRNAs). The 3’ untranslated region (3’ UTR) of the A20 gene was confirmed to be a direct target of miR-125 [73]. MiR-125b was found to be negatively correlated with A20 levels [74], thus strengthening and prolonging NF-$\kappa$B activity. Furthermore, miR-125b promotes the process of inflammation in RA by activating NF-$\kappa$B activity [73], and miR-125b is overexpressed in the plasma or serum of RA patients as well [75]. Similarly, miR-19b can also positively regulate NF-$\kappa$B signaling through synergistic inhibition of A20 [76]. Furthermore, miR-19b is of great importance in the pathology of RA [73], as transfection of miR-19b mimics the increased inflammatory activation of primary fibroblast-like synovial cells in RA [76]. In contrast, although miR-29 has been reported to increase the abundance of A20 mRNA and protein in cancer cells [77], arthritic pathology in miR-29a-deficient mice is reduced [78].

**Others**

In addition to the abovementioned regulators, there are other regulators of A20. For example, following TCR activation, a negative feedback regulation mechanism is formed.

| Table 1 The target and mechanism of A20 regulating arthritis |
|-------------------------------------------------------------|
| **Target** | **Pro-inflammation approach** | **Effect of A20** | **Consequence** |
|-----------------------------------------------|------------------|-----------------|----------------|
| NF-$\kappa$B | Trigger the formation of numerous pro-inflammatory cytokines like IFN-$\gamma$, TNF-$\alpha$, IL-1$\beta$, IL-6 | Restrict its activation | Reduced pro-inflammation cytokines |
| Casp1 | Cell pyroptosis | Lower activation of Casp1 and inhibit pyroptosis dependent on Casp1 | Cell survival and secretion of cytokines is blocked |
| | NLRP3 activation, IL-1 and IL-18 secretion | Downregulate the transcription of NLRP3, ASC, pro-caspase1, pro-IL-1, and IL-18 | Inhibited NLRP3 assembly and activation |
| RIPK1 | Activation of NF-$\kappa$B | Remove K63-linked ubiquitin chains from RIPK1 and add K48-linked ubiquitin on RIPK1 | Degradation of RIPK1 |
| MAPKs | Secretion of IL-17A | Deubiquitination of TRAF6 and prevent the prolonged phosphorylation of JNK | Blocked IL-17 production |
| Unphosphorylated RIPK3 | Macrophages necroptosis | Reduce phosphorylation of RIPK3 | Macrophages survived |
| TNFR1 signal complexes | Macrophages necroptosis | Protect these complexes from being degraded through ZnF7 domain | Macrophages survived |
stimulation, A20 is degraded by paracaspase MALT1 [79, 80]. In vitro recombinant A20 preferentially hydrolyses K48-linked chains, but phosphorylated A20 cleaves K63-linked chains and enhances ZnF4-mediated substrate ubiquitination [23]. Furthermore, the inhibitory ability of A20 will increase if A20 is phosphorylated at Ser381 by IKKβ [81]. Therefore, we infer that the phosphorylation of A20 is essential for its function. The RNA-binding protein RC3H1 binds the 3′ UTR of A20 through ROQ and Zn-finger domains, and knockdown of RC3H1 contributes to increased expression of the A20 protein [82]. In addition, physiological conditions also have a certain effect on A20. Vascular A20 expression can also be regulated by high glucose via O-glucosamine-N-acetylation-dependent ubiquitination and proteasomal degradation [83]. Reactive oxygen species promoted A20 expression via increased H3K4me3 modification of histones on the A20 promoter domain [84]. Moreover, by modulating A20 ubiquitlization, RING-type zinc finger protein 114 (RNF114) stabilizes A20 protein [85]. In addition, γ-tocotrienol (γTE) upregulates A20 attributed to increasing phosphorylation of translation initiation factor 2, IκBα, and JNK [86]. Finally, the anti-inflammatory action of gibberellic acid is also thought to significantly increase A20 mRNA and protein levels [87].

**Single nucleotide polymorphisms (SNPs) of the A20 gene and arthritis**

Single nucleotide polymorphisms (SNPs) perform a critical function in determining the risk profile of inflammatory and autoimmune diseases. In the A20 gene locus, SNPs are related to inflammatory diseases and autoimmune diseases, including RA [24], psoriasis [88], systemic lupus erythematosus (SLE) [89], and inflammatory bowel disease [90]. The majority of these disease-associated SNPs are located up- or downstream of the A20 noncoding regions or are in intronic regions, suggesting that SNPs in the A20 locus may affect its functional expression. Indeed, two SNPs in the coding region of A20 inducing nonsynonymous mutations (rs5029941/A125 V and rs2230926/F127C) reduce its expression and function [91, 92]. These mutations are both located in exon 3 and have been suggested to affect the DUB activity of A20. In addition to these two coding variants, many SNPs have been identified in noncoding regions and affect the function of cell- and activation-specific enhancers. See details in Catrysse et al. [14], Wertz et al. [23], and Ma et al. [93].

RA has a tight association with several disease-associated SNPs of A20, including rs2230926, rs6920220, and rs10499194 [94, 95]. Studies have established that rs2230926: T > G is strongly associated with RA [94, 96]; this SNP is found to result in a change from phenylalanine to cysteine at position 127, which encodes A20 protein’s deubiquitinase domain and can result in a decreased ability of A20 to suppress NF-κB activation [92]. Associating SNPs in specific genes with arthritis helps to associate genotypes and/or molecular types with prognosis or treatment responses, such as responses to TNF blocked [94, 97]. The Rs2230926 TG genotype and rs146534657 AG genotype have been linked to poor outcomes in RA patients [94]. In addition, patients harboring rs2230926/F127C and rs610604, psoriasis-associated risk genes, respond positively to TNF blocked, so they may be potential prognostic markers [88]. In addition, rs7749323 is a dinucleotide polymorphism of TT > A and can function as an enhancer element binding for NF-κB and the special AT-rich binding protein 1 (SATB1), thereby enabling these proteins to interact with the A20 promoter [98]. Deletion of the TT > A enhancer will result in an enhanced inflammatory response, production of autoantibodies, and inflammatory arthritis [99]. Interestingly, some SNPs in the A20 locus may protect people from RA, such as rs13207033, which is not associated with RA in isolation but is associated in multivariate models [100]. In the absence of rs13207033, the combination of rs6920220 and rs5029937 alleles significantly increased the risk of RA [101]. Rs675520 and rs9376293 were associated with increased joint destruction in ACPA-positive patients but not in ACPA-negative patients [102].

HA20 is a rare and early-onset autoinflammatory syndrome due to nonsense and frameshift mutations located in the ZnF4 or the DUB domains of A20 [25]. HA20 patients frequently show increased NF-κB signaling and NLRP3 inflammasome activity, and they develop polyarthritis, which can be the initial disease manifestation [25, 26]. The expression of A20 depends on the topologically associated subdomain (sub-TAD), which contains four enhancers and is important for the functions of regulating the expression of hA20 in vivo and preventing the development of inflammatory pathology [99]. Additionally, the p.(lys91*) a20 mutation can cause hA20, as a result of a severely truncated protein with an impaired OTU domain, which leads to caspase-8-dependent enhanced NLRP3 inflammasome activation and possibly leads to systemic juvenile arthritis and psoriatic arthritis [103]. However, autoinflammatory disease activity in HA20 patients is strongly patient-dependent, ranging from grossly normal to severe multi-organ inflammation, and thus treatment strategies need to vary with each individual [26, 27].

**Mouse models for studying the role of A20 in arthritis**

A20-deficient mice exhibit different extents of manifestations that resemble arthritis. Lee et al. first created
A20−/− mice that lack A20, but early death of the mice hindered in-depth research [104]. Since then, several A20-associated mouse models have been developed, and they have helped demonstrated the exact relationship between A20 and arthritis; such mouse models include the following: A20myel-KO, targeting myeloid cells [21], A20mZnF7/mZnF7, targeting the ZnF7 motif, and A20ZF4ZF7, targeting ZnF4 and ZnF7 motifs [29]. Here, we summarize their features and how these genotypes imitate typical manifestations of arthritis. Finally, we list some other A20-related models to help study the etiological and pathological role of A20 (Table 2).

A20−/−

To clarify how A20 generally exerts its influence on related inflammation, Lee et al. created A20−/− mouse models in 2000 (Fig. 3) [104]. These A20-deficient mice suffered from severe inflammation and cachexia and died prematurely thereafter. Both unaided and histological observations showed that there was damage and inflammation to different extents in their liver, kidney, intestines, and bone marrow. A20−/− mice were also hypersensitive to low doses of TNF and LPS given that they all died within 2 h of injection [104].

The inability of A20−/− mice to inhibit the NF-κB reaction led to the above symptoms, which are strongly associated with rheumatoid arthritis [104]. It is likely that high levels of TNF-α, secreted by macrophages, induce Th1-mediated inflammation [109]. This is a key cascade in the development of rheumatoid arthritis, causing classic features such as consequent synovial inflammation and joint destruction [110].

A20myel-KO

The A20myel-KO mouse strain, developed by Matmati et al., is deficient in A20 specifically in myeloid cells and demonstrates polyarthritis-like features. Unlike the A20−/− mice described above, A20myel-KO did not suffer from cachexia or prematurely die within 2 weeks, so researchers employ this strain to obtain more data.

The most obvious disparity between A20myel-KO and its wild-type littermates was that these myeloid-deficient mice spontaneously developed polyarthritis in their joints, which closely resembled the histopathological

### Table 2 Overview of A20-related mouse models

| Genotype | Domain          | Alteration | Phenotype                                                                 | References                  |
|----------|-----------------|------------|---------------------------------------------------------------------------|-----------------------------|
| A20−/−   | Full knock out  | Full knock out | Severe inflammation, cachexia, and premature deaths                      | Lee et al. 2000 [104]       |
| A20myel-KO | Myeloid-specific | Exon IV and V | Chronic inflammation in ankles, tibial joint and tarsojoint, massive cartilage and bone destruction | Mammati et al. 2011 [21]    |
| A20ZnF7| ZnF7            | C764A/C767A | Inflammatory arthritis with splenomegaly, symmetrical swelling joints    | Polyrakitis et al. 2019 [29]|
| A20ZF7-CC| ZnF7            | C764A/C767A | Psoriasis and psoriatic arthritis                                         | Razani et al. 2020 [28]     |
| A20ZF4ZF7| ZnF4 and ZnF7   | C609A/C612A | Perinatal lethality, multiorgan inflammation, tissue damage              | Razani et al. 2020 [28]     |
| A20ZF4ZF7| ZnF4 and ZnF7   | C609A/C612A | Polyarthritis-like manifestations                                         | Razani et al. 2020 [28]     |
| Tnfaip3OTU| OTU             | C103A       | Splenomegaly, †IL-1 in response to oral dextran sulfate sodium; †IL-6, †NF-κB signaling | Lu et al. 2013 [13]         |
| Tnfaip3ZnF4| ZnF4            | C609A/C613A | Chronic inflammation in younger mice and autoimmune syndrome in older mice | De et al. 2014 [15]         |
| Tnfaip3OTU| OTU             | C103A       | Sensitive to TNF, LPS, †MOG-EAE                                          | Wertz et al. 2015 [23]      |
| Tnfaip3ZnF4| ZnF4            | C609A/C612A | Sensitive to TNF, †MOG-EAE                                              | Wertz et al. 2015 [23]      |
| Tnfaip3OTU| OTU             | I325N       | Mild inflammation in pancreatic islets                                   | Zammit et al. 2019 [105]    |
| Tnfaip3C243Y| OTU             | C243Y       | Spontaneous inflammatory pathology                                       | Zammit et al. 2019 [105]    |
| Tnfaip3T108L| OTU             | T108A/T102L | Healthy                                                                  | Zammit et al. 2019 [105]    |
| A20B    | B cell-specific | Exon IV and V | †IL-6, †B cell proliferation                                            | Chu et al. 2011 [106]       |
| A20CD4| CD4 T cell-specific | Exon IV and V | Chronic inflammation in younger mice and autoimmune syndrome in older mice | Drennan et al. 2016 [107]   |
| DC ACT  | CD11c-specific  |           | †Inflammatory mediators in kidney                                       | Lu et al. 2019 [108]        |

OTU ovarian tumor, MOG-EAE myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis, DC ACT Cd11c-Cre* A20myel-KO.
manifestations in humans. For example, A20\textsuperscript{myel-KO} animals suffered from chronic inflammation in their ankles, tibiotalar joints, and tarsal joints, and they also exhibited extensive cartilage and bone destruction [21]. These are all classical manifestations of rheumatoid arthritis. Other abnormal symptoms, such as infiltration of immune cells, erosion, and an increase in blood monocytes and neutrophils, have also been noted [21]. It has also been observed that the serum levels of several arthritis-associated or inflammation-associated cytokines, such as TNF, IL-1β, IL-6, and monocyte chemoattractant protein-1 (MCP-1), were augmented [21]. These cytokines have been proven to be related to the basic pathological process of rheumatoid arthritis. All these autoimmune disorders, regardless of whether they are present in bones, cartilage or blood cells, are hallmarks of rheumatoid arthritis.

Contradicting to initial postulations, the development of polyarthritis in A20\textsuperscript{myel-KO} mice was not dependent on TNF, T lymphocytes, or B lymphocytes, which are involved in the pathogenesis of rheumatoid arthritis [50]. Instead, it was highly associated with TLR4-MyD88-induced signaling and IL-6 [21].

\textbf{A20}\textsuperscript{mZnF7/mZnF7} strain could be potential in studying human psoriasis and psoriatic arthritis, especially those psoriasis patients with anti-cyclic citrullinated peptide (anti-CCP) antibodies, a type of antibody that exists in rheumatoid arthritis. This mouse strain was initially designed to dissect the functional domains in A20 and elucidate their effects on arthritis. Before the advent of this model, evidence has indicated that the Znf7 domain was capable of binding to linear ubiquitin chains to regulate the TNFR1 signaling pathway, which initiates apoptosis and the necroptosis caspase cascade, thereby leading to inflammatory responses [22, 111].

The A20\textsuperscript{mZnF7/mZnF7} strain could be potential in studying human psoriasis and psoriatic arthritis, especially those psoriasis patients with anti-cyclic citrullinated peptide (anti-CCP) antibodies, a type of antibody that exists in rheumatoid arthritis. This mouse strain was initially designed to dissect the functional domains in A20 and elucidate their effects on arthritis. Before the advent of this model, evidence has indicated that the Znf7 domain was capable of binding to linear ubiquitin chains to regulate the TNFR1 signaling pathway, which initiates apoptosis and the necroptosis caspase cascade, thereby leading to inflammatory responses [22, 111].

The same strategic cysteine-to-alanine mutation at 764 and 767 was applied by Polykratis et al. and Razani et al., except that this genotype was respectively referred to as A20\textsuperscript{mZnF7/mZnF7} and A20\textsuperscript{ZF7--CC} [28, 29].

In contrast to A20\textsuperscript{−/−} mice, A20\textsuperscript{mZnF7/mZnF7} mice did not die prematurely, but they weighed less than control mice. A20\textsuperscript{mZnF7/mZnF7} developed inflammatory arthritis with splenomegaly, and researchers observed symmetrical swelling in their ankles, wrists, and toes [29]. Computed tomographic results of their paws revealed bone erosion and reformulation of bone, but compared with symptoms in A20\textsuperscript{myel-KO} [21], the symptoms in A20\textsuperscript{mZnF7/mZnF7} animals were less severe. A20\textsuperscript{mZnF7/mZnF7} also showed higher serum concentrations of two inflammatory cytokines, TNF and IL-6 [30]. A20\textsuperscript{ZF7--CC}, the same genotype but with a different name, displayed typical manifestations of psoriasis and psoriatic arthritis, including dactylitis-like erosion in their distal phalanx and nails, enthesitis, aberrant bone formation, erosion, and dermal inflammation [28]. Point mutations in neither OTU nor ZF4 displayed these psoriatic arthritis-like manifestations [28]. Additionally, A20\textsuperscript{ZF7--CC/ZF7--CC} exhibited increased numbers of CD4+ and CD8+ T cells along with an increased proportion of memory phenotype T cells relative to A20\textsuperscript{OTU/OTU}, A20\textsuperscript{ZF4/ZF4}, and their wild-type littermates [28]. In a similar comparison, the NF-kB and JNK pathways were found to be more active in naïve A20\textsuperscript{ZF7--CC/ZF7--CC} T cells, indicating that the arthritis-like symptoms are T cell-dependent [28]. Intriguingly, A20\textsuperscript{ZF7--CC/ZF7--CC} mice showed elevated levels of anti-CCP antibodies, which is more prevalent in human rheumatoid arthritis than it is in psoriatic arthritis [28]. Hence, this mouse model may constitute a model of synchronized rheumatoid arthritis and psoriatic arthritis.

\textbf{A20}\textsuperscript{ZF4ZF7/ZF4ZF7} The fact that A20\textsuperscript{ZF7/ZF7} mice far outlives A20\textsuperscript{−/−} animals [28] implies that the role of A20 in regulating inflammation and cell death requires mutual effort of Znf7 and other domains. Razani et al. generated an A20\textsuperscript{ZF4ZF7/ZF4ZF7} model that harbors point mutations in its Znf4 and Znf7 motifs using CRISPR-directed gene targeting [28]. They also generated a tissue-specific model that imitates polyarthritis. A20\textsuperscript{ZF4ZF7/ZF4ZF7} mice exhibited perinatal lethality and multiorgan inflammation similar to what was observed in A20\textsuperscript{−/−} mice [104], and they showed gross inflammation and tissue damage, which was not observed in A20\textsuperscript{OTU/OTU}, A20\textsuperscript{ZF4/ZF4}, or A20\textsuperscript{ZF7--CC/ZF7--CC} mice [28]. Upon TNF stimulation, A20\textsuperscript{ZF4ZF7/ZF4ZF7} MEFs expressed elevated mRNA that is dependent on NF-kB [28]. Consequent signaling research revealed that A20\textsuperscript{ZF4ZF7/ZF4ZF7} displayed increased phosphorylated IκKB, expression of phosphorylated IκBa and IKK activity [28].

With the help of the Cre/loxP site-specific recombination system, tissue-specific A20\textsuperscript{ZF4ZF7/ZF4ZF7} models have also been put to use. It is worth mentioning that myeloid-specific A20\textsuperscript{ZF4ZF7/ZF4ZF7} mice exhibit histological and pathophysiological features with polyarthritis, including immune cell filtration, cartilage destruction, and bone erosion [30]. The mice also demonstrated abundant inflammatory cytokines such as TNF and IL-6 in their serum, which was consistent with the A20\textsuperscript{myel-KO} model [30].

\textbf{Others} There have been controversies over in vivo studies. For example, Tnfaip3\textsuperscript{OTU} data contradicts A20C103A data. Tnfaip3\textsuperscript{OTU} mice, with impeded DUB activity, and Tnfaip3\textsuperscript{ZF4}, with abolished E3 ligase activity, were
generated to delineate the role of DUB activity and ZnF4 in restricting TNF signaling. In this study, both Tnfaip3\textsuperscript{z4Ub/z4Ub} and Tnfaip3\textsuperscript{1325N} displayed higher levels of IL-1 in response to oral dextran sulfate sodium, higher levels of IL-6, and increased NF-κB signaling [13]. However, harboring the same mutation as Tnfaip3\textsuperscript{OTU}, A20C103A mice were grossly normal and exhibited no inflammation compared with heterozygotes and WT littermates [15]. A reasonable explanation for this could be that the DUB activity of A20 collaborates with ZnF4, ZnF7, or other DUBs, such as cylindromatosis [15, 112]. This calls for more mouse models to enable greater depths of study.

As mentioned above, A20 is modified by phosphorylation. Ingrid et al. demonstrated that A20 phosphorylation leads to enhanced K63-linked polyubiquitin chain cleavage performed by the OTU domain, while ZnF4 acts as an accelerator of substrate ubiquitination in vivo through Tnfaip3\textsuperscript{z4Ub/z4Ub} Tnfaip3\textsuperscript{1325N} and Tnfaip3\textsuperscript{1207L} [23]. Furthermore, three TNFAIP3 alleles, Tnfaip3\textsuperscript{1325N}, Tnfaip3\textsuperscript{243Y}, and Tnfaip3\textsuperscript{1207L}, bearing missense alterations of different extents in the OTU region, showed diminished A20 phosphorylation and elevated immune responses [105]. In comparison, Tnfaip3\textsuperscript{243Y} developed spontaneous inflammatory pathology, while Tnfaip3\textsuperscript{1325N} only showed mild inflammation in pancreatic islets, and Tnfaip3\textsuperscript{1207L} appeared healthy [105]. Based on these results, Zammit et al. proposed that aberrant mutations in the OTU region modulate A20 phosphorylation and that there might be a tradeoff between impeded A20 activity and microbial resistance [105].

In addition to A20\textsuperscript{myel-KO} mice, B cell-specific knockout A20\textsuperscript{flox} mice exhibited augmented IL-6 levels and promoted B cell proliferation and cell survival. Younger mice developed chronic inflammation featuring increased myeloid cells, Tregs and effector T cells, while older mice developed autoimmune syndrome [106]. In CD4 T cell-specific A20 knockout mice, A20\textsuperscript{GFP}, there was no spontaneous phenotype. However, A20 deficiency strongly reduced the number of invariant natural killer T (NKT) cells [107]. Further results supported the role of A20 in the proliferation of NKT cells, especially NKT1 and NKT2 [107]. Cd11c-Cre\textsuperscript{+}A20\textsuperscript{flox/wt} mice lack A20 in Cd11c-expressing myeloid cells. They displayed elevated inflammatory mediators in their kidneys, and they are more susceptible to inflammatory bowel disease [108].

**Conclusion**

After years of exploration in the treatment of arthritis, there is still a lack of an efficient treatment, although TNF inhibitors have been widely used. Based on these anti-inflammatory mechanisms of A20 and evidence of its capacity for arthritic inhibition discussed above, we suggest that A20 is a potential target for arthritis therapies, with the advantages of its multipath effect on arthritis pathogenesis. Therefore, we could design small molecules or genetic techniques to target A20, thus exerting an influence on the expression of A20 to regulate arthritis. Moreover, the A20 rs2230926 TG and rs146534657 AG genotypes may be linked to poor outcome in RA patients. Hence, we could assess these genes to predict the risk of arthritis and sequentially make some precautionary measures to retard the development of arthritis.

Moreover, research on A20 is still far from finished, not only concerning its ability but also regarding its functional domains. The appearance of mouse models A20\textsuperscript{mZnF7/mZnF7} and A20\textsuperscript{z4ZnF7/z4ZnF7} inspired us to develop more types of models to probe the function of other domains and the potent synergy between different motifs, thus achieving a complete understanding of A20 and its related diseases.
References

1. Oikonomopoulou K, Diamandis EP, Hollenberg MD, Chandran V. Proteinases and their receptors in inflammatory arthritis: an overview. Nat Rev Rheumatol. 2018;14(3):170–80.

2. Sparks JA. Rheumatoid Arthritis. Ann Intern Med. 2019;171(1):1c–16.

3. Hunter DJ, Biemra-Zeintna S. Osteoarthritis. Lancet. 2019;393(10182):1745–59.

4. Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM. Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Ann Rheum Dis. 2018;77(6):849–54.

5. Urbano PCM, Aguirre-Gamboa R, Ashikov A, van Heeswijk B, Krippner-Heidenreich A, Tijssen H, Li Y, Azevedo VF, Smits LJT, Hoentjen F, et al. TNF-alpha-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-alpha blockade-driven IL-17A expression. J Allergy Clin Immunol. 2018;142(1):255–71.

6. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor –alpha-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-alpha blockade-driven IL-17A expression. J Allergy Clin Immunol. 2018;142(1):255–71.

7. Beringer A, Miossec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2013;9(9):54.

8. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Rev Rheumatol. 2015;11(10):574–82.

9. Dasgupta A, Martens A, Priem D, Hoste E, Vetters J, Rennen S, Catrysse L, Voet S, Deelen MJ, Declerq W, Vandenabeele P, et al. A20 inhibits STAT1 expression in myeloid cells: a novel endogenous regulatory mechanism preventing development of enthesis. Ann Rheum Dis. 2017;76(3):585–92.

10. Dinarello CA. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612–32.

11. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205–19.

12. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. Nat Rev Rheumatol. 2019;15(1):9–17.

13. Wistuba MD, Green S, Sarma V, Lawrence B. Tumor necrosis factor α induction of novel gene products in human endothelial cells including a macrophage-specific chemokine. J Biol Chem. 1990;265(5):2973–8.

14. Martens A, van Loo G. A20 at the crossroads of cell death, inflammation, and autoimmunity. Cold Spring Harb Perspect Biol. 2020;12(1):a029148. https://doi.org/10.1101/cshperspect.a029148.

15. Lu TT, Onizawa M, Hammer GE, Turer EE, Yin Q, Danno K, Ageldis A, Shifin N, Advincula R, Herrera J, et al. Dimerization and ubiquitin-mediated recruitment of A20, a complex deubiquitinating enzyme. Immunity. 2013;38(5):896–905.

16. Catryse L, Vereecke L, Beyaert M, van Loo G. A20 in inflammation and autoimmunity. Trends Immunol. 2014;35(1):22–31.

17. De A, Dainichi T, Rathinam CV, Ghosh S. The deubiquitinase activity of A20 is dispensable for NF-kα signaling. EMBO Rep. 2014;15(7):775–83.

18. Zhang Q, Lenardo MJ, Baltimore D. 30 years of NF-kB: a blossoming of relevance to human pathology. Cell. 2017;168(1):2–37–57.

19. Sun SC. The non-canonical NF-kappaB pathway in immunity and inflammation. Nat Rev Immunol. 2017;17(9):545–58.

20. Shembade N, Ma A, Harhay EW. Inhibition of NF-kappaB signaling by A20 through disruption of ubiquitin enzyme complexes. Science. 2010;330(5969):1135–9.

21. Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430(7000):654–9.

22. Priem D, Devos M, Druwe S, Martens A, Slowicka K, Ting AT, Pasparakis M, Declerq W, Vandenbergabe P, van Loo G, et al. A20 protects cells from TNF-induced apoptosis through linear ubiquitin-dependent and -independent mechanisms. Cell Death Dis. 2019;10(1):692.

23. Wu P, van’t Veer AM, Akritopoulou E, Ketterer N, Verstappen SMM. Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Ann Rheum Dis. 2018;77(6):849–54.

24. Brenner D, Blaser H, Mak TW. Regulation of tumour necrosis factor –alpha-induced protein 3 (TNFAIP3)/A20 acts as a master switch in TNF-alpha blockade-driven IL-17A expression. J Allergy Clin Immunol. 2018;142(1):255–71.

25. Zhao X, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, Yang D, Demirkaya E, Takeuchi M, Tsai WL, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67–73.

26. Aeschlimann FA, Batu ED, Canna SW, Go E, Gu AL, Hofmann P, Lewis HL, Ozcn S, Schwartz DM, Stone DL, et al. A20 haploinsufficiency (HA20): clinical phenotype and disease course of patients with a newly recognised NF-kβ-mediated autoinflammatory disease. Ann Rheum Dis. 2018;77(5):728–35.

27. Schwartz DM, Blackstone SA, Sampaio-Moura N, Rosenzweig S, Burmester GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Mysler E, Sleeman MA, et al. Type I interferon signature predicts response to JAK inhibition in haploinsufficiency of A20. Ann Rheum Dis. 2020;79(3):429–31.

28. Zhao X, Wu P, van’t Veer AM, Akritopoulou E, Ketterer N, Verstappen SMM. Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register. Ann Rheum Dis. 2018;77(6):849–54.

29. Polykratis A, Martens A, Eren RO, Shiasaki Y, Yamagishi M, Yamaguchi Y, Uemura S, Miura M, Holzbmann B, Kollas G, et al. A20 prevents psoriatic arthritis-like disease and inflammation. Nat Immunol. 2020;21(4):422–33.

30. Polykratis A, Martens A, Eren RO, Shiasaki Y, Yamagishi M, Yamaguchi Y, Uemura S, Miura M, Holzbmann B, Kollas G, et al. A20 prevents psoriatic arthritis-like disease and inflammation. Nat Immunol. 2020;21(4):422–33.

31. Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004;430(7000):654–9.

32. Vande Walle L, Van Opdenbosch N, Jacques P, Linton AT, Danila MI, Cofield SS, Shadick N, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition of rheumatoid arthritis. Nat Rev Rheumatol. 2018;14(2):64.

33. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–57.

34. Beringer A, Miossec P. Systemic effects of IL-17 in inflammatory arthritis. Nat Rev Rheumatol. 2019;15(8):491–501.

35. Afonina IS, Zhong Z, Karin M, Beyaert R. Limiting inflammation-the negative regulation of NF-κappaB and the NLRP3 inflammasome. Nat Immunol. 2017;18(8):861–7.

36. Nisula S. Experimental arthritis: anti-TNF kills the macrophage response. Nat Rev Rheumatol. 2018;14(2):664.

37. Wampler Muskinard T, Vashistl P, Dorschner JM, Jensen MA, Chrabot BS, Kern M, Curtis JR, Danila M, Coffield SS, Shadick N, et al. Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis. Ann Rheum Dis. 2017;76(10):1757–62.

38. Burmeister GR, Rigby WF, van Vollenhoven RF, Kay J, Rubbert-Roth A, Kelman A, Dimonaco S, Mitchell N. Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis. 2016;75(6):1081.
monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis. 2017;76(6):1020–30.

41. Liu R, Chen Y, Fu W, Wang S, Cui Y, Zhao X, Lei ZN, Hettinghouse A, Liu J, Wang C, et al. Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis. Ann Rheum Dis. 2019;78(11):1524–35.

42. Zhang X, Zhang H, Xu C, Li X, Li M, Wu X, Pu W, Zhou B, Wang H, Li D, et al. Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis. Nat Commun. 2019;10(1):14158.

43. Cookley H, Chokshi S, Williams RO, Abraham S, Taylor PC. Increase in circulating TH17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis. Arthritis Res Th. 2016;18(1):103.

44. Zilberman-Rudenko J, Carpenter I, Kreike M, Meloni L, Verstrepen L, Kensche T, Dikic I, et al. The ubiquitin––polyubiquitin chains via its zinc finger 7. EMBO J. 2012;31(19):3845–55.

45. Verhelst K, Carpentier I, Kreike M, Meloni L, Verstrepen L, Kensche T, Dikic I, et al. Inhibits LUBAC-mediated NF-κB activation by binding linear polyubiquitin chains via its zinc finger 7. EMBO J. 2012;31(19):3845–55.

46. Garg AV, Ahmed M, Vallejo AN, Ma A, Gaffen SL. The deubiquitase A20 mediates feedback inhibition of interleukin-17 receptor signaling. Sci Sig. 2013;6(278):ra44.

47. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. CRISPR/Cas9-based gene editing as therapy for osteoarthritis. Ann Rheum Dis. 2015;74(1):21–22.

48. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Exploration of CRISPR/Cas9-based gene editing as therapy for osteoarthritis. Arthritis Res Ther. 2016;18(1):303.

49. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Restoration of oxidant signaling suppresses proarthritogenic T cell effector activation and regulation to therapeutics. Nat Rev Immunol. 2019;19(8):477–89.

50. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Mechanism and regulation of NLRP3 inflammasome activation. Trends Biochem Sci. 2017;42(1):55–62.

51. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. Ann Rheum Dis. 2014;73(6):1202–10.

52. Inflammatory disease. Cell Death Differ. 2015;22(2):225–35.

53. Mastrobuoni G, Friedel CC, Dölken L, et al. RC3H1 post-transcriptionally regulates A20 mRNA and modulates the activity of the IKK/NF-κB pathway. Cell Mol Life Sci. 2017;74(11):2095–113.

54. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nat Commun. 2014;5:239–47.

55. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Immunity. 2015;43(3):239–47.

56. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nat Immunol. 2014;15(3):239–47.

57. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nat Immunol. 2014;15(3):239–47.

58. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nat Immunol. 2014;15(3):239–47.

59. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nature. 2015;528(7580):243–8.

60. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nature. 2015;528(7580):243–8.

61. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nature. 2015;528(7580):243–8.

62. Mathews RJ, Robinson JI, Battellino M, Wong C, Taylor JC, Eyre S, et al. Transcription factor DREAM regulates the deubiquitase A20 and mediates inflammation. Nature. 2015;528(7580):243–8.
ubiquitination and degradation of the anti-inflammatory protein A20 to accelerate atherosclerosis in diabetic ApoE-null mice. PLoS One. 2010;5(12):e14240.

84. Li Y, Zhang P, Wang C, Han C, Meng J, Liu X, Xu S, Li N, Wang Q, Shi X, et al. Immune responsive gene 1 (IRG1) promotes endotoxin tolerance by increasing A20 expression in macrophages through reactive oxygen species. J Biol Chem. 2013;288(23):16225–34.

85. Rodriguez MS, Egaña I, Lopitz-Otsoa F, Aillet F, Lopez-Mato MP, Dorrorsoro A, Lobato-Gil S, Sutherland JD, Barrio R, Trigueros C, et al. The RING ubiquitin E3 RNF114 interacts with A20 and modulates NF-κB activity and T-cell activation. Cell Death Dys. 2014;5(8e1):1399.

86. Wang Y, Park NY, Jiang Y, Ma A, Jiang Q. Vitamin E γ-tocotrienol inhibits cytokine-stimulated NF-κB activation by induction of anti-inflammatory A20 via stress adaptive response due to modulation of sphingolipids. J Immunol. 2015;195(1):126–33.

87. Reihi JA, Malcomson B, Bertselsen A, Cheung V, Friedman D, Ferran C. Single nucleotide polymorphism in TNFAIP3, a feedback inhibitor of nuclear factor-kappaB and the neighbor of TNFAIP3, with systemic lupus erythematosus susceptibility. Arthritis Res. 2009;11(2):R42.

88. Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, McGreal NM, Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Garcia-Carbonell R, Yao SJ, Das S, Guma M. Dysregulation of intestinal epithelial cell RIPK pathways promotes chronic inflammation in the IBD gut. Front Immunol. 2019;10:1094.

89. Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ottmann W, Shifrin N, Petrini MA, Kamboh MI, Manz S, et al. Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet. 2008;40(9):1062–4.

90. Lodolce JP, Kolodziej LE, Rhee L, Kariuki SN, Franek BS, McGreal NM, Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, Shifrin N, Garcia-Carbonell R, Yao SJ, Das S, Guma M. Dysregulation of intestinal epithelial cell RIPK pathways promotes chronic inflammation in the IBD gut. Front Immunol. 2019;10:1094.

91. Zhu L, Wang L, Wang X, Zhou L, Liao Z, Xu L, Wu H, Ren J, Li Z, Yang L, et al. Characteristics of A20 gene polymorphisms and clinical significance in patients with rheumatoid arthritis. J Transl Med. 2015;13:215.

92. Mele A, Cervantes JR, Chien V, Friedman D, Ferran C. Single nucleotide polymorphisms at the TNFAIP3/A20 locus and susceptibility/resistance to inflammatory and autoimmune diseases. Adv Exp Med Biol. 2014;809:163–83.

93. Shimane K, Kochi Y, Horita T, Ikari K, Amano H, Hirakata M, Okamoto A, Yamada R, Myozuen K, Suzuki A, et al. The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum. 2010;62(2):574–80.

94. Koizumi N, Kikuchi N, Nakamura K, Shigeta H, Kanbe Y, Ogawa T, Horiuchi A, Katoh K, Imai Y, Osawa S, et al. Effect of TNFAIP3 gene (A20) polymorphisms on the susceptibility/resistance to early-onset rheumatoid arthritis. Arthritis Rheum. 2008;60(3):956–63.

95. Knevel R, de Rooy DP, Gregersen PK, Lindqvist E, Wilson AG, Gröndal G, Zhemakova A, van Nies JA, Toes RE, Tsonaka R, et al. Studying associations between variants in TRAF1-C and TNFAIP3-OLIG3 and the progression of joint destruction in rheumatoid arthritis in multiple cohorts. Ann Rheum Dis. 2012;71(10):1753–3.

96. Rajamaki K, Keski-Rahkonen A, Seppanen M, Kuusmin M, Vahasaio P, Trotta L, Vaananen A, Glumov V, Keski-Rahkonen P, Kaarteenaho R, et al. Haploinsufficiency of A20 impairs protein-protein interaction and leads to caspase-8-dependent enhancement of NLRP3 inflammasome activation. RDMP Open. 2018;4(2e4):e00740.

97. Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000;289(5488):2350–4.

98. Zammit NW, Siggs OM, Gray PE, Horikawa K, Langley DB, Walters SN, Daley SR, Loetsch C, Warren J, Yap JY, et al. Denisovan, modern human and mouse TNFAIP3 alleles tune A20 phosphorylation and immunity. Nat Immunol. 2019;20(10):1299–301.

99. Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Włodziszewicz E, Soberon V, Schenten D, Mack B, Reuelshöfer M, et al. B cells lacking the tumour suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood. 2011;117(7):2227–36.

100. Drennan MB, Govindarajan S, Verheugen E, Coquet JM, Staal J, McGuire C, Taghon T, Lederer G, Beyaert R, van Loo G, et al. NKT sublineage specification and survival requires the ubiquitin-modifying enzyme TNFAIP3/A20. J Exp Med. 2016;213(10):1973–81.

101. Lu X, Rudemiller NP, Wen Y, Ren J, Hammer GE, Griffiths R, Privratsky JR, Yang B, Sparks MA, Crowley SD. A20 in myeloid cells protects against hypertension by inhibiting dendritic cell-mediated T-cell activation. Circ Res. 2019;125(12):1055–66.

102. Chua-Aguilera CJ, Möller B, Yawalkar N. Skin manifestations of rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritides. Clin Rev Allergy Immunol. 2017;53(3):371–93.

103. Cappelli LC, Thomas MA, Bingham CO 3rd, Shah AA, Darrah E. Immune checkpoint inhibitor-induced inflammatory arthritis as a model of autoimmune arthritis. Immunol Rev. 2020;294(1):106–23.

104. Taraborrelli L, Peltear N, Montinaro A, Kupka S, Rieser E, Hartwig T, Sarr A, Darding M, Draper P, Haas TL, et al. LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L. Nat Commun. 2018;9(1):3910.

105. Verhelst K, van Loo G, Beyaert R. A20: attractive without showing cleavage. Nat Rev Immunol. 2012;12(11):774–83.

106. Chu Y, Vahl JC, Kumar D, Heger K, Bertossi A, Włodziszewicz E, Soberon V, Schenten D, Mack B, Reuelshöfer M, et al. B cells lacking the tumour suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. Blood. 2011;117(7):2227–36.

107. Drennan MB, Govindarajan S, Verheugen E, Coquet JM, Staal J, McGuire C, Taghon T, Lederer G, Beyaert R, van Loo G, et al. NKT sublineage specification and survival requires the ubiquitin-modifying enzyme TNFAIP3/A20. J Exp Med. 2016;213(10):1973–81.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.